Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06221774CT.gov Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Clear Cell Renal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tinengotinib (this asset) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P1/2 | CC · 47 |
| Everolimus | Peking University First Hospital | P2 | BB |
| Axitinib | University of California, San Francisco | P3 | B |
| Nivolumab | Exelixis | P2 | B |
| Pazopanib | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | P2 | B |
| Toripalimab | RenJi Hospital | P2 | B |
| Modified Vaccinia Virus Ankara-5T4 Antigen | Oxford BioMedica | P3 | B |
| Zanzalintinib | Kelly Fitzgerald, MD | P2 | B |
| Belzutifan | José Claudio Casali da Rocha | P2 | B |
+31 more in the Clear Cell Renal Carcinoma cohort
Other indications for Tinengotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cholangiocarcinoma | — | P3 | B · 59 |
| Triple-Negative Breast Carcinoma | — | P1/2 | B · 57 |
| Cancer | — | P1/2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tinengotinib in Clear Cell Renal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tinengotinib-clear-cell-renal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →